166 related articles for article (PubMed ID: 35115620)
1. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
Lee J; Ham JY; Park HY; Jung JH; Kim WW; Kang B; Chae YS; Lee SJ; Lee IH; Lee NY
Sci Rep; 2022 Feb; 12(1):1842. PubMed ID: 35115620
[TBL] [Abstract][Full Text] [Related]
2. The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
Menko FH; Jeanson KN; Bleiker EMA; van Tiggelen CWM; Hogervorst FBL; Ter Stege JA; Ait Moha D; van der Kolk LE
Eur J Hum Genet; 2020 Aug; 28(8):1020-1027. PubMed ID: 32300191
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
5. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
[TBL] [Abstract][Full Text] [Related]
6. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
7. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
9. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
[TBL] [Abstract][Full Text] [Related]
10. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
Larsen MJ; Thomassen M; Tan Q; Lænkholm AV; Bak M; Sørensen KP; Andersen MK; Kruse TA; Gerdes AM
BMC Med Genomics; 2014 Jan; 7():9. PubMed ID: 24479546
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
12. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
Haddad JM; Robison K; Beffa L; Laprise J; ScaliaWilbur J; Raker CA; Clark MA; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Genet Couns; 2021 Dec; 30(6):1570-1581. PubMed ID: 33904624
[TBL] [Abstract][Full Text] [Related]
13. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
[TBL] [Abstract][Full Text] [Related]
15. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
16. Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Lattimore V; Parsons MT; Spurdle AB; Pearson J; Lehnert K; Sullivan J; Lintott C; Bawden S; Morrin H; Robinson B; Walker L
Breast Cancer Res Treat; 2021 Feb; 185(3):583-590. PubMed ID: 33113089
[TBL] [Abstract][Full Text] [Related]
17. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore.
Zhang Z; Ishak NDB; Que FVF; Chua ZY; Chan SH; Chiang J; Yie JNY
Hered Cancer Clin Pract; 2023 Apr; 21(1):5. PubMed ID: 37046302
[TBL] [Abstract][Full Text] [Related]
19. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
[TBL] [Abstract][Full Text] [Related]
20. Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition.
Agata S; Tognazzo S; Alducci E; Matricardi L; Moserle L; Barana D; Montagna M
Sci Rep; 2020 Aug; 10(1):13987. PubMed ID: 32814805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
